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Abstract: International Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC) has established reference meas-
urement procedures (RMPs) for the most popular enzymes. 
Manufacturers should assign values to commercial calibra-
tors traceable to these RMPs to achieve equivalent results 
in clinical samples, independent of reagent kits, instru-
ments, and laboratory where the measurement is carried 
out. The situation is, however, far from acceptable. Some 
manufacturers continue to market assays giving results 
that are not traceable to internationally accepted RMPs. 
Meanwhile, end-users often do not abandon assays with 
demonstrated insufficient quality. Of the enzyme measure-
ments, creatine kinase (CK) is satisfactorily standardized 
and a substantial improvement in performance of marketed 
γ-glutamyltranspeptidase (GGT) assays has been demon-
strated. Conversely, aminotransferase measurements often 
exceed the desirable analytical performance because of the 
lack of pyridoxal-5-phosphate addition in the commercial 
reagents. Measurements of lactate dehydrogenase (LDH), 
alkaline phosphatase (ALP), and α-amylase (AMY) still show 
major disagreement, suggesting the need for improvement 
in implementing traceability to higher-order references. This 
is mainly the result of using assays with different analytical 
selectivities for these enzymes. The definition by labora-
tory professionals of the clinically acceptable measurement 
uncertainty for each enzyme together with the adoption by 
EQAS of commutable materials and use of an evaluation 
approach based on trueness represent the way forward for 
reaching standardization in clinical enzymology.
Keywords: enzymes; reference procedures; reference 
values; traceability; uncertainty.
Introduction
Serum enzymes are among the 20 most frequently ordered 
tests in clinical laboratories, as they represent important 
biomarkers for the diagnosis and monitoring of diseases 
of the liver, pancreas, skeletal muscle, bone, etc. [1]. Con-
sequently, the analytical validity and standardization of 
their measurements have a central role and may become a 
matter of patient safety, thus potentially affecting the way 
enzyme tests should be used to provide optimal care [2]. It 
is now globally recognized that to be accurate and equiva-
lent for long term, laboratory results should be traceable to 
higher-order references (methods and/or materials) [3]. In 
this regard, it is essential to build an unbroken metrologi-
cal traceability chain that starts from the definition of the 
measurand and ends, through a calibration hierarchy, at the 
level of the patient’s result [4]. Through a suitable metrologi-
cal traceability chain, the in vitro diagnostics (IVD) manu-
facturers can reliably transfer the measurement trueness 
from the highest level of the metrological hierarchy to the 
calibrators of commercial analytical systems used in clinical 
laboratories to obtain unbiased results on clinical samples.
Previously, we discussed how standardization in clin-
ical enzymology and the achievement of interlaboratory 
agreement of enzyme catalytic activity measurements may 
represent a challenge for the theory of metrological trace-
ability in laboratory medicine [5, 6]. Furthermore, it is now 
clear that having all traceability tools in place is not often 
enough to ensure that patient care remains consistent, as 
the efficacy of traceability implementation should also 
be considered [4, 7]. The aim of this article is to update 
the knowledge in the field 6 years since our last review on 
this journal [6], with special reference to the progress and 
impact of enzyme measurement standardization.
Establishing a reference system in 
clinical enzymology
An enzyme measurand cannot be described only by kind 
of quantity, name of enzyme and of system, but requires 
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also the specified measurement procedure and especially 
the indicator component of the measured reaction [8]. As 
a consequence, the numerical results of enzyme catalytic 
activity are method-dependent, i.e. they depend entirely on 
the experimental conditions under which measurements 
are made (pH and nature of buffer, nature and concen-
tration of substrate, presence of activators and inhibitors, 
measurement temperature). In the standardization of 
enzyme assays, a reference measurement procedure (RMP), 
which defines the conditions under which a given enzyme 
activity is measured, occupies therefore the highest level of 
the traceability chain [9]. In performing RMPs for enzymes, 
technical aspects related to gravimetry, volumetry, pH, 
reaction temperature, and photometry must be carefully 
controlled to achieve a level of measurement uncertainty as 
lower as possible; meanwhile, a comprehensive list of rel-
evant sources of uncertainty should be assembled in order 
to identify the most relevant ones (Figure 1) [10, 11].
In the last 14 years, the IFCC has recommended RMPs 
for seven enzymes [12–18], which are now listed in the 
database of the Joint Committee on Traceability in Labora-
tory Medicine (JCTLM) [19]. Few enzyme reference materi-
als (ERM) are also listed (for aspartate aminotransferase 
[AST], γ-glutamyltranspeptidase [γGT], and α-amylase 
[AMY]), whereas reproduction and characterization of 
new ERMs for alanine aminotransferase (ALT), creatine 
kinase (CK) and lactate dehydrogenase (LDH) are ongoing 
[20]. It should be noted that the lack of ERMs is not a major 
issue for the implementation of enzyme measurement 
standardization, as manufacturers may better approach 
it by splitting a panel of native clinical samples with an 
accredited reference laboratory performing RMP and 
then calibrate their commercial systems in accordance 
with correlation results obtained using the RMP-assigned 
values of clinical samples [5]. To perform this exercise, 
nine accredited laboratories providing a reference service 
for enzyme measurements are currently present on the 
JCTLM database, four from Europe and five from China 
(http://www.bipm.org/jctlm/home.do).
Meanwhile, it has been noted that the lack of proper 
reference intervals may hamper the implementation of 
standardization in enzymology [6]. Standardization can 
indeed modify enzyme results and without adequate ref-
erence intervals this situation can impair the interpreta-
tion of the results and, paradoxically, worsen the patient’s 
outcome [2, 21]. The introduction of enzyme reference 
measurement systems to provide traceable patient results 
have therefore been followed by the definition of traceable 
reference intervals to provide more congruent and effec-
tive information to clinicians. In particular, traceable ref-
erence intervals have been established for AST, ALT, γGT, 
LDH, CK, alkaline phosphatase (ALP), and AMY first in 
Caucasian adults and afterwards in Asian individuals [17, 
18, 22–26]. Table 1 reports a synopsis of traceable reference 
intervals for enzymes obtained in European and Asian 
subjects. Note the slight difference in ALT and LDH values 
between the two groups and the marked increase in ALP, 
AMY, and CK (only in males) values in Asian adults.
Several examples in literature show that the applica-
tion of the metrological traceability approach works well 
in harmonizing enzyme results in clinical samples [27, 28].
Fulfilling expectations
Traceability implementation by industry
Previously, we described what we consider the major 
steps in the achievement of standardization of enzyme 
measurements [6]. After the establishment of refer-
ence systems, we put on the top the implementation of 
Figure 1: Example of uncertainty budget for the alanine aminotrans-
ferase (ALT) reference measurement procedure.
Adapted from ref. [10].
Table 1: Traceable reference intervals for enzymes with established 
reference measurement systems obtained in European and Asian 
adults. 
Enzyme  
 
European  
 
Asian
Females   Males Females   Males
AST   11–34    14–32 
ALT   8–41   9–59   11–31   14–54
GGT   6–40   12–68   15–43   15–68
LDH   125–220    138–235 
CK   34–145   46–171   40–152   58–261
AMY   31–107    47–136 
ALP   33–98   43–115   40–106   48–131
Data from refs. [17, 18, 22–26].
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traceability by diagnostic manufacturers to them. The 
European Union (EU) directive on IVD medical devices 
obliges manufacturers to ensure traceability of their 
measuring systems to recognized higher-order references 
[29]. However, the introduction of correctly standardized 
assays in enzymology appears not be occurring smoothly. 
In 2006, a first multicenter study involving 70 laboratories 
from three European countries assessed the traceability 
of enzyme results to RMPs using assays from six manu-
facturers [30]. Although for ALT results were relatively 
good, major drawbacks were shown for AST, CK, γGT, 
LDH, and AMY. More recently, the same group reassessed 
the traceability of enzyme measurements in four Euro-
pean countries [31]. Authors concluded that CK is now 
satisfactorily standardized and a substantial improve-
ment in performance of marketed GGT assays is evident. 
Conversely, aminotransferases, LDH, and AMY still show 
major disagreement among assays, suggesting the need 
for improvement in implementing traceability. Interest-
ingly, assay performance varied considerably also within 
users of instruments from the same manufacturer. This is 
mainly dependent on the availability on the same plat-
forms of various reagent options having different analyti-
cal selectivities for the enzyme declared to be measured. 
The case of aminotransferases is very illustrative. Almost 
all manufacturers still market assays with or without the 
addition of pyridoxal-5-phosphate (P-5′-P), in both cases 
declaring to be traceable to RMP. However, it is impossible 
to calibrate procedures for aminotransferases that do not 
incorporate P-5′-P using a procedure that does, such as the 
RMP, because the ratio of pre-formed holoenzyme to apo-
enzyme differs among specimens. Another recent study 
confirmed that assays without P-5′-P activation are often 
unable to fulfill bias specifications when aminotrans-
ferase results are compared to RMPs [32].
Abandonment of non-specific assays by 
end-users
The commercial availability of methods with different 
selectivities for an enzyme measurand points to the need 
for laboratories to take responsibility to move to assays 
displaying similar selectivity when compared to RMP. 
According to a simple market law, if users continue to 
ask for and buy non-specific assays, manufacturers will 
indeed continue to produce and market them.
The concept of the reference measurement system is 
working only if the RMP and corresponding commercial 
procedures have identical, or at least very similar, selec-
tivity for the measured enzyme [9]. A recently performed 
survey of 73 Italian laboratories has checked the spread 
of different methods for enzymes measurements [33]. 
The percentage of laboratories declaring to use methods 
employing IFCC analytical principles was markedly 
increased for all common enzymes when compared to 
2006. However, the central question is: “Those who 
believe to report enzyme traceable results, did they accu-
rately recover the targets set by the RMP?” Using ALP as an 
example, while in the mentioned survey, 80% of laborato-
ries declared to use methods based on the IFCC RMP ana-
lytical principle, a recent study evaluating the trueness of 
ALP measurements using serum pools with target values 
assigned by RMP showed that in a group of 13 first-rate 
laboratories, only three (23%) fulfilled the desired goal for 
bias at all three tested ALP concentrations and only one 
provided data with a dispersion always within the uncer-
tainty of the target value set by the reference laboratory 
[34]. Interestingly, the ability to meet the goal was clearly 
dependent on the analytical system used.
External quality assessment schemes 
(EQAS) using commutable materials and 
 trueness-based grading
We emphasized several times how the lack of properly 
structured EQAS prevents the objective evaluation of the 
reliability of measuring systems and of the quality of ana-
lytical measurements provided by clinical laboratories 
[4, 6, 35, 36]. Only true value assignment by RMP to EQAS 
commutable materials allows objective evaluation of the 
performance of enzyme measurements through a trueness-
based (instead of inferior consensus-based) grading of 
the competency of participating clinical laboratories. The 
fulfillment of requirements for the applicability of EQAS 
results in the evaluation of the performance of participat-
ing laboratories in terms of traceability of their measure-
ments involves both technical and economic efforts by 
EQAS organizers that are still limiting their introduction 
[37, 38]. It is, however, clear that these aspects have to be 
immediately solved since EQAS that meet metrological 
criteria have unique benefits that add substantial value 
to the practice of laboratory medicine [2]. This has been 
shown by Cobbaert et al. [39], who, using commutable and 
RMP-targeted EQAS materials, were able to demonstrate a 
significant improvement of enzyme standardization in the 
Netherlands from 2005 to 2010. The percentage of labo-
ratories fulfilling the clinically allowable bias increased 
from ~10% to ~70% for LDH, from ~40% to ~60% for AST, 
and from ~70% to ~90% or more for ALT and γGT, respec-
tively. By the way, the study has also shown, by comparing 
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the interlaboratory CV to the intralaboratory CVs, that 
enzymes are among the analytes with further harmoniza-
tion potential.
Professionals establish analytical 
 performance specifications (APS)
In addition to the definition of reference systems, the labo-
ratory profession is expected to establish, in agreement 
to recognized models, APS for enzymes measurements to 
make their determination clinically usable and to ensure 
that the measurement error does not prevail on the result 
[35]. During the conference held in Milan in 2014, the hier-
archy of models for deriving APS was revised [40]. In par-
ticular, three models to set APS have been recommended: 
model 1, based on the effect of analytical performance on 
clinical outcomes; model 2, based on components of bio-
logical variation of the measurand; and model 3, based 
on state-of-the-art of the measurement [40]. We strongly 
support the addition of APS derived from these models to 
the EQAS categorization previously published by Miller 
et al. [37] as criteria to evaluate the performance of labo-
ratories participating to EQAS. Miller’s categories 1 and 2, 
which fulfill the metrological requirements highlighted 
above, should be each split in two sub-categories: 1/2A, in 
which Milan high-order models 1 and 2 for APS are applied, 
and 1/2B, in which other low-order models are employed.
It is still under discussion under which APS model 
different measurands should be placed [41]. Since valid 
outcome data are generally not available, the biologi-
cal variability model is applied to enzymes. However, 
Carobene et al. [42], in assessing the validity of published 
biological variability data for ALT, AST and γGT, showed 
a wide range of values derived from inconsistent proto-
cols and/or wrong statistical derivation. Therefore, there 
is a need for critical appraisal of such publications and 
only those that fulfill recommendations for biological 
variability data production should be considered in order 
to derive APS [43]. Table 2 reports performance specifi-
cations for allowable maximum uncertainty in enzyme 
measurements by clinical laboratories, obtained from 
studies using robust protocols to evaluate biological vari-
ability [1].
Summarizing considerations
The findings discussed in this review incontrovert-
ibly show that having all traceability tools for the most 
Table 2: Allowable maximum uncertainty for enzyme measurements 
performed by clinical laboratories.
Enzyme 
 
Quality level
Minimum   Desirable   Optimum
AST   ± 9.3%   ± 6.2%   ± 3.1%
ALT   ± 14.6%   ± 9.7%   ± 4.9%
γGT   ± 5.6%   ± 3.7%   ± 1.9%
LDH   ± 6.5%   ± 4.3%   ± 2.2%
CK   ± 17.1%   ± 11.4%   ± 5.7%
ALP   ± 4.5%   ± 3.0%   ± 1.5%
AMY   ± 6.6%   ± 4.4%   ± 2.2%
important enzymes in place is not enough to obtain their 
standardization. The IFCC standardization seems to be 
often declared, but not soundly adhered to and/or cor-
rectly implemented. Furthermore, some manufacturers 
continue to sell on the market assays that are not trace-
able to internationally accepted reference systems. There-
fore, a sizeable bias of the analytical results towards the 
RMP values is often observed. We can consider three main 
aspects that oppose the complete achievement of stand-
ardization in clinical enzymology: (a) legislation short-
comings, (b) manufacturing limitations, and (c) lack of a 
proactive role of professionals, who do not fully perceive 
the advantages of enzyme standardization.
Legislation
The EU directive on IVD medical devices gives only generic 
indications on traceability. Compliance with the directive 
is indicated through the CE (“Communautés Europée-
nnes”) marking of conformity on diagnostic products, but 
at present, no normative verification by a third party of the 
manufacturer’s statements is provided. CE mark does not 
mean that IVD manufacturers has transferred trueness 
successfully and that uncertainty of calibrators meets 
clinical needs [4]. Meanwhile, the JCTLM database has no 
legal value and the ISO 15189 accreditation standard does 
not specifically require traceability to JCTLM references. 
“Accuracy assessment” by existing EQAS is usually based 
on consensus to peer groups using the same analytical 
equipment and not on the true value assignment. This has 
created a situation where clinical laboratories can meet 
governmental regulations despite consistently reporting 
biased enzyme results. The hope is that the forthcom-
ing EU regulatory framework will require supervision of 
notified bodies, with access to external expertise (e.g. sci-
entific experts, reference laboratories), well-defined post-
market surveillance activities, with enhanced involvement 
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of laboratory professionals, and more transparency by 
manufacturers in providing performance data and trace-
ability of IVD devices.
IVD manufacturers
Manufacturers may explicitly or implicitly object to stand-
ardization for marketing or cost reasons: in the absence 
of mandatory requirements and of clear requests from the 
profession, they have no interest in new investments. To 
fulfill the request of a global market, most continue to 
offer different reagents for the same enzyme, not having 
a perception of the competitive advantage in offering only 
RMP-traceable assays.
Professionals
The advantages of enzyme standardization are often 
not fully perceived, neither by laboratorians nor by cli-
nicians. Resistance of professionals originates from 
common human conservatism because changes require 
efforts, such as establishment of new reference intervals 
and explanations to clinicians and patients. Instead of 
requesting manufacturers to change, most of us just waits 
for the new proposals from industry. As mentioned earlier 
[2], to become relevant in the healthcare environment, 
laboratory professionals have to change their attitude 
from one of being defensive to one that is outward looking 
and innovative.
The way forward
Fifteen years have passed from the publication on this 
journal of the first review promoting enzyme standardi-
zation by implementing traceability to higher-order RMPs 
[9]. Over this period, we saw (and we were part of) many 
efforts contributing to transfer the theory in the daily 
clinical practice. Quoting Sir Paul McCartney, “the road 
is still long and winding”, but we should not despair. In 
particular, we strongly believe that the adoption of APS 
based on the clinically acceptable measurement uncer-
tainty for each enzyme together with the provision by 
EQAS organizers of commutable materials and use of an 
evaluation approach exclusively based on trueness rep-
resents the way forward to reach the standardization in 
clinical enzymology. This will definitively help those man-
ufacturers that produce superior products to demonstrate 
the superiority of those products and oblige users (and 
consequently industry) to abandon assays with demon-
strated insufficient quality.
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